Products and Services

Are you interested in Cell Line Development, the development of a New Biological Drug, Biosimilar or an improved bioprocess?

We will bring your project faster to success! UGA Biopharma has longstanding expertise and know-how in cell line development, bioprocess optimization, downstream development and analytics as well as media and feed development. This makes us to an ideal partner for your development projects.

UGA Biopharma - The start has to be right!

 

Ready To Use Biosimilar Cell Lines read more

Adalimumab Biosimilar           

Full package ready for sales now: 

Research Cell Bank (RCB) including safety testing 

Optimized fermentation process (USP) 

Optimized downstream purification process (DSP) and analytics 

Including proof of activity of the expressed protein 



If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.

 

Aflibercept Biosimilar           

Aflibercept is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development is required to develop a biosimilar like Aflibercept.


If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.

 

Anakinra Biosimilar           

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.

Bevacizumab Biosimilar           

Remarkable Bevacizumab clone stability for at least 10 weeks of cultivation.


If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Certolizumab Biosimilar           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Darbepoetin alfa Biosimilar           

Biosimilary of Darbepoetin alfa expressing cell line could be improved. Please consider the isolectical focusing (IEF) gel of Darbepoetin alfa biosimilars and the originator.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Eculizumab Biosimilar           

Very good biosimilarity achieved in a challenging Eculizumab development project (IgG2/4 hybrid antibody). 


If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Etanercept Biosimilar           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Ipilimumab Biosimilar           
Typical charge profil of ther reference medical product of Ipilimumab.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Laronidase Biosimilar           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Natalizumab Biosimilar           
The primary structure of a biosimilar has to be identical to the originator molecule. The result of the peptide mapping of the Natalizumab biosimilar is depicted here.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Nivolumab Biosimilar           
A product concentration over 3 g/L has been obtained during a Nivolumab consistency run in stirred bioreactors.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
  
Pembrolizumab Biosimilar           
Pembrolizumab (IgG4) biosimilar development project has been finalized in a very short time line – according to the High Speed Workflow of UGA Biopharma!

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.


Pertuzumab Biosimilar           
Outstanding productivity higher than 5 g/L reached during the pertuzumab development project!

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Dupilumab Biosimilar           
An outstanding product concentration higher than 7 g/L could be reached during the Dupilumab development project! The first CHOice® Medium works very well for Dupilumab clones.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.

Under Development

Alirocumab Biosimilar           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Imiglucerase Biosimilar           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.

 

Mepolizumab Biosimilar           

This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.

 

Omalizumab Biosimilar           
A product concentration of 3 g/L has been obtained during the Omalizumab biosimilar development project.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Dulaglutide Biosimilar           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Elosulfase Biosimilar           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Erenumab Biosimilar           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Galsulfase Biosimilar           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Idursulfase Biosimilar           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Panitumumab Biosimilar           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
 

Disclaimer

Most of the listed medical products (ready to use biosimilars, biosimilars under development or biosimilar cell lines) are subject of patents, patent applications and supplementary protection certificates. Therefore, UGA Biopharma GmbH does only provide the medical product in small amounts and solely for research and development performed in accordance with the research exemption and the market authorization privilege as defined in DIRECTIVE 98/44/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 July 1998 on the legal protection of biotechnological inventions and in DIRECTIVE 2004/27/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use (implemented into the German Patent Act in Section 11 No. 2 and 2b) in order to protect the rights of the patent holder(s) of the medical product. Otherwise, until the expiration of the patents and supplementary protection certificates related to the medical products, it is not allowed to produce, offer, put on the market or use the offered product which is subject of the intellectual property rights or to possess such a product for the purposes referred to within the territorial scope of the intellectual property rights. In case of contravention, a penalty for breach of contract from the person acting against the above mentioned regulations can be demanded.           





Contact

UGA Biopharma GmbH
Neuendorfstraße 20a
16761 Hennigsdorf
Germany
E-mail:  info@ugabiopharma.com This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: +49(0)3302 / 2024900